EMEA-000236-PIP05-18

Key facts

Invented name
Eylea
Active substance
aflibercept
Therapeutic area
Ophthalmology
Decision number
P/0115/2019
PIP number
EMEA-000236-PIP05-18
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of retinopathy of prematurity
Route(s) of administration
Intravitreal use
Contact for public enquiries
Bayer AG

Tel. +49 30300139003
E-mail: clinical-trials-contact@bayer.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number
EMEA-C-000236-PIP05-18
Compliance opinion date
15/10/2021
Compliance outcome
positive

Decision

Related content

How useful was this page?

Add your rating